As for the price issue, Kongstvedt said that usually happens when a pharmaceutical protected by a patent has few competitors because we allow a free market in the U.S., unlike pretty much any other nation in the world. Combined with our third-party payment system in which most people are protected from the impact of that pricing when a drug is covered, it provides a powerful motivation to drug manufacturers to jack prices up until they actually can look down upon the International Space Station, Kongstvedt said.
MDWatch providers are licensed in 35 states, and we open new states every few months
Your healthcare provider or pharmacist will give you instructions on how and where to self-administer the injection
As such, if everything continues to run smoothly, it will likely reach shelves by late 2027
Lets look closer at these comparisons
If these cost much less, I dont think there would be a debate about coverage given their clinical effectiveness, he says